Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allogr
Authors:
Journal: Transplant international : official journal of the European Society for Organ Transplantation
Publication Type: Journal Article
Date: 2016
DOI: NIHMS715060
ID: 26265179
Abstract
The advent of more potent immunosuppressants led to the first successful human upper extremity transplantation in 1998. At this time, >100 upper extremity transplants, 30 face transplants, and a variety of other vascularized composite allotransplantation (VCA) procedures have been performed around the world. VCA recipients present unique challenges for transplantation. The incidence of acute rejection exceeds 80% in hand and face transplantation and is well documented, whereas reports about antibody-mediated rejection and chronic rejection remain scarce. Immunosuppression protocols commonly used at US centers are derived from solid organ transplantation protocols. Novel approaches to minimize rejections in VCA may include improved HLA matching and considerations toward cytomegalovirus infection status. New graft preservation techniques may decrease immunogenicity prior to transplant. Novel monitoring methods such as valid biomarkers, ultrasound biomicroscopy, and sentinel flaps may enable earlier diagnosis of rejection. Cell-based therapies are being explored to achieve immunosuppressive regimen minimization or even tolerance induction. The efficacy of local immunosuppression in clinical VCA remains controversial. In conclusion, although immunosuppressive strategies adapted from SOT have demonstrated good midterm results, focusing on the unique features of VCA grafts may enable additional, more specific treatment strategies in the future and improved long-term graft outcomes.
Chemical List
- Antibodies|||Biomarkers|||HLA Antigens|||Immunosuppressive Agents
Reference List
- Harrison JH, Merrill JP, Murray JE. Renal homotransplantation in identical twins. Surg Forum. 1956;6:432–6.|||Murray JE, et al. Study on transplantation immunity after total body irradiation: clinical and experimental investigation. Surgery. 1960;48:272–84.|||Merrill JP, et al. Successful transplantation of kidney from a human cadaver. JAMA. 1963;185:347–53.|||Gilbert R. Transplant is successful with a cadaver forearm. Med Trib Med News. 1964;5:20–22.|||Gilbert R. Hand transplanted from cadaver is reamputated. Med Trib Med News. 1964;5:23–25.|||Murray JE. Organ transplantation (skin, kidney, heart) and the plastic surgeon. Plast Reconstr Surg. 1971;47(5):425–31.|||Tobin GR, et al. The history of human composite tissue allotransplantation. Transplant Proc. 2009;41(2):466–71.|||Diaz-Siso JR, et al. Vascularized composite tissue allotransplantation--state of the art. Clin Transplant. 2013;27(3):330–7.|||Dubernard JM, et al. Human hand allograft: report on first 6 months. Lancet. 1999;353(9161):1315–20.|||Hofmann GO, et al. Vascularized knee joint transplantation in man: a report on the first cases. Transpl Int. 1998;11(Suppl 1):S487–90.|||Monaco AP. Transplantation of the larynx--a case report that speaks for itself. N Engl J Med. 2001;344(22):1712–4.|||Fischer S, et al. Functional outcomes of face transplantation. Am J Transplant. 2015;15(1):220–33.|||Pomahac B, et al. Three patients with full facial transplantation. N Engl J Med. 2012;366(8):715–22.|||Selvaggi G, et al. Abdominal wall transplantation: surgical and immunologic aspects. Transplant Proc. 2009;41(2):521–2.|||Sun Q, Zheng J, Zhao C. Nerve transplantation and accompanying peripheral vessels for repair of long nerve defect. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2012;26(7):832–6.|||Birchall M. Tongue transplantation. Lancet. 2004;363(9422):1663.|||Jones TR, Humphrey PA, Brennan DC. Transplantation of vascularized allogeneic skeletal muscle for scalp reconstruction in renal transplant patient. Transplant Proc. 1998;30(6):2746–53.|||Johannesson L, et al. Uterus transplantation trial: 1-year outcome. Fertil Steril. 2015;103(1):199–204.|||Zhang LC, Zhao YB, Hu WL. Ethical issues in penile transplantation. Asian J Androl. 2010;12(6):795–800.|||Shores JT, Brandacher G, Lee WA. Hand and Upper Extremity Transplantation: An Update of Outcomes in the Worldwide Experience. Plast Reconstr Surg. 2014|||Petruzzo P, et al. Clinicopathological Findings of Chronic Rejection in a Face Grafted Patient. Transplantation. 2015|||Weissenbacher A, et al. Antibody-mediated rejection in hand transplantation. Transpl Int. 2014;27(2):e13–7.|||Chandraker A, et al. The management of antibody-mediated rejection in the first presensitized recipient of a full-face allotransplant. Am J Transplant. 2014;14(6):1446–52.|||Duhamel P, et al. Anti-HLA sensitization in extensively burned patients: extent, associated factors, and reduction in potential access to vascularized composite allotransplantation. Transpl Int. 2015|||Cinamon U, et al. A simplified testing system to evaluate performance after transplantation of human skin preserved in glycerol or in liquid nitrogen. J Burn Care Rehabil. 1993;14(4):435–9.|||Richters CD, et al. Immunogenicity of glycerol-preserved human cadaver skin in vitro. J Burn Care Rehabil. 1997;18(3):228–33.|||Kotton CN. CMV: Prevention, Diagnosis and Therapy. Am J Transplant. 2013;13(Suppl 3):24–40. quiz 40.|||Couzi L, et al. Direct and Indirect Effects of Cytomegalovirus-Induced gammadelta T Cells after Kidney Transplantation. Front Immunol. 2015;6:3.|||Bonastre J, et al. Factors influencing acute rejection of human hand allografts: a systematic review. Ann Plast Surg. 2012;68(6):624–9.|||Schneeberger S, et al. Cytomegalovirus-related complications in human hand transplantation. Transplantation. 2005;80(4):441–7.|||Weissenbacher A, et al. Vascularized composite allografts and solid organ transplants: similarities and differences. Curr Opin Organ Transplant. 2013;18(6):640–4.|||Fischer S, et al. Acute rejection in vascularized composite allotransplantation. Curr Opin Organ Transplant. 2014;19(6):531–44.|||Sinha I, Pomahac B. Split rejection in vascularized composite allotransplantation. Eplasty. 2013;13:e53.|||Mathes DW, et al. Split tolerance to a composite tissue allograft in a swine model. Transplantation. 2003;75(1):25–31.|||Kueckelhaus M, et al. Utility of sentinel flaps in assessing facial allograft rejection. Plast Reconstr Surg. 2015;135(1):250–8.|||Dvorak HF, et al. Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med. 1979;150(2):322–37.|||Bhan AK, Mihm MC, Jr, Dvorak HF. T cell subsets in allograft rejection. In situ characterization of T cell subsets in human skin allografts by the use of monoclonal antibodies. J Immunol. 1982;129(4):1578–83.|||Lian CG, et al. Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury. Mod Pathol. 2014;27(6):788–99.|||Petruzzo P, Dubernard JM. The International Registry on Hand and Composite Tissue allotransplantation. Clin Transpl. 2011:247–53.|||Diaz-Siso JR, et al. Initial Experience of Dual Maintenance Immunosuppression With Steroid Withdrawal in Vascular Composite Tissue Allotransplantation. Am J Transplant. 2015|||Schneeberger S, et al. First forearm transplantation: outcome at 3 years. Am J Transplant. 2007;7(7):1753–62.|||Unadkat JV, et al. Investigation of antibody-mediated rejection in composite tissue allotransplantation in a rat limb transplant model. Transplant Proc. 2009;41(2):542–5.|||Landin L, et al. CD3+-mediated rejection and C4d deposition in two composite tissue (bilateral hand) allograft recipients after induction with alemtuzumab. Transplantation. 2009;87(5):776–81.|||Kaufman CL, et al. Graft vasculopathy in clinical hand transplantation. Am J Transplant. 2012;12(4):1004–16.|||Petruzzo P, et al. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant. 2011;11(4):808–16.|||Cendales LC, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant. 2008;8(7):1396–400.|||Thione A, et al. Late nail lesions rejection in a stable bilateral forearm allograft at 60 months posttransplantation. Ann Plast Surg. 2014;73(5):612–4.|||Tsutsui H, et al. Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: results from a 5-year serial intravascular ultrasound study. Circulation. 2001;104(6):653–7.|||Kanitakis J, et al. Graft vasculopathy in the skin of a human hand allograft: implications for diagnosis of rejection of vascularized composite allografts. Transpl Int. 2014;27(11):e118–23.|||Mundinger GS, et al. Histopathology of chronic rejection in a nonhuman primate model of vascularized composite allotransplantation. Transplantation. 2013;95(10):1204–10.|||Unadkat JV, et al. Composite tissue vasculopathy and degeneration following multiple episodes of acute rejection in reconstructive transplantation. Am J Transplant. 2010;10(2):251–61.|||Menke J, et al. The effect of ischemia/reperfusion on the kidney graft. Curr Opin Organ Transplant. 2014;19(4):395–400.|||Rao J, Lu L, Zhai Y. T cells in organ ischemia reperfusion injury. Curr Opin Organ Transplant. 2014;19(2):115–20.|||Lunsford KE, Barbas AS, Brennan TV. Recent advances in immunosuppressive therapy for prevention of renal allograft rejection. Curr Opin Organ Transplant. 2011;16(4):390–7.|||Slegtenhorst BR, et al. Ischemia/reperfusion Injury and its Consequences on Immunity and Inflammation. Curr Transplant Rep. 2014;1(3):147–154.|||Thiyagarajan UM, Ponnuswamy A, Bagul A. Thymoglobulin and its use in renal transplantation: a review. Am J Nephrol. 2013;37(6):586–601.|||Weissenbacher A, et al. Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation. Immunotherapy. 2010;2(6):783–90.|||Ramirez CB, I, Marino R. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther. 2007;7(1):137–48.|||Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584–91.|||Schneeberger S, Khalifian S, Brandacher G. Immunosuppression and monitoring of rejection in hand transplantation. Tech Hand Up Extrem Surg. 2013;17(4):208–14.|||Khalifian S, et al. Facial transplantation: the first 9 years. Lancet. 2014;384(9960):2153–63.|||Chan KM, et al. Improving peripheral nerve regeneration: from molecular mechanisms to potential therapeutic targets. Exp Neurol. 2014;261:826–35.|||Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31(5):335–40.|||McAlister VC, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant. 2006;6(7):1578–85.|||Schnider JT, et al. Site-specific immunosuppression in vascularized composite allotransplantation: prospects and potential. Clin Dev Immunol. 2013;2013:495212.|||Kiwanuka H, et al. Evolution of ethical debate on face transplantation. Plast Reconstr Surg. 2013;132(6):1558–68.|||Ali F, Dua A, Cronin DC. Changing paradigms in organ preservation and resuscitation. Curr Opin Organ Transplant. 2015|||De Vlaminck I, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014;6(241):241ra77.|||Kueckelhaus MIA, Fischer S, Kumamaru K, Alhefzi M, Bueno EM, Wake N, Gerhard-Herman MD, Rybicki FJ, Pomahac B. Non-invasive monitoring of immune rejection in face transplant recipients. Plast Reconstr Surg. 2015 in press.|||Haas M, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272–83.|||Schneeberger S, et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg. 2013;257(2):345–51.|||Leonard DA, Kurtz JM, Cetrulo CL., Jr Achieving immune tolerance in hand and face transplantation: a realistic prospect? Immunotherapy. 2014;6(5):499–502.|||Leonard DA, et al. Vascularized composite allograft tolerance across MHC barriers in a large animal model. Am J Transplant. 2014;14(2):343–55.|||Jindal R, et al. Spontaneous Resolution of Acute Rejection and Tolerance Induction With IL-2 Fusion Protein in Vascularized Composite Allotransplantation. Am J Transplant. 2015|||Gharb BB, et al. Effectiveness of topical immunosuppressants in prevention and treatment of rejection in face allotransplantation. Transplantation. 2013;95(10):1197–203.|||Gajanayake T, et al. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. Sci Transl Med. 2014;6(249):249ra110.|||Solhjou Z, et al. Emerging therapies targeting intra-organ inflammation in transplantation. Am J Transplant. 2015;15(2):305–11.